CRISPR Therapeutics to Report Q3 Earnings: Is a Beat in Store? [Yahoo! Finance]
CRISPR Therapeutics AG - Common Shares (CRSP)
Last crispr therapeutics ag - common shares earnings: 8/7 05:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/crsp/real-time
Company Research
Source: Yahoo! Finance
The Zacks Consensus Estimate for sales is pinned at $6.4 million, while the same for earnings is pegged at a loss of $1.33 per share. CRISPR Therapeutics' top line currently includes grants and collaboration revenues from its partnership with large-cap biotech Vertex Pharmaceuticals VRTX. CRSP and partner VRTX's one-shot gene therapy, Casgevy, was approved for two blood disorders, sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), in the United States and Europe in late 2023/early 2024. Vertex leads the global development and commercialization of Casgevy under the terms of the 2021 agreement with support from CRISPR Therapeutics. Casgevy is the first marketed product in CRSP's portfolio. Though the therapy's launch activities are already underway in several countries, we expect the company to have started recording Casgevy sales in the third quarter. Our model estimates for CRISPR's share of the gene therapy sales are pegged at $5 million. Investors w
Show less
Read more
Impact Snapshot
Event Time:
CRSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CRSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CRSP alerts
High impacting CRISPR Therapeutics AG - Common Shares news events
Weekly update
A roundup of the hottest topics
CRSP
News
- Capsida Biotherapeutics to Present at 7th Annual Evercore HealthCONx Conference [Yahoo! Finance]Yahoo! Finance
- Down 47% Since March, Is CRISPR Therapeutics Stock a Buy on the Dip? [Yahoo! Finance]Yahoo! Finance
- 3 Monster Stocks in the Making [Yahoo! Finance]Yahoo! Finance
- Genome Editing Market Size Projected to Reach USD 32.72 Billion by 2032, Driven by Advances in CRISPR and Gene Therapies – SNS Insider [Yahoo! Finance]Yahoo! Finance
- The Gene Revolution: Transforming Lives through Gene Editing Therapeutics [Yahoo! Finance]Yahoo! Finance
CRSP
Earnings
- 11/5/24 - Beat
CRSP
Sec Filings
- 11/13/24 - Form 4
- 11/12/24 - Form 144
- 11/5/24 - Form 10-Q
- CRSP's page on the SEC website